Abstract
Cytokine release syndrome (CRS) and immune effector cell–associatedneurotoxicitysyndrome(ICANS)areadverseevents (AEs) of particular concern with bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies used in treating diffuse large B-cell lymphoma (DLBCL).1 Here are 3 things you should know about managing these AEs.
| Original language | English |
|---|---|
| Pages (from-to) | 40-43 |
| Number of pages | 4 |
| Journal | ONCOLOGY (United States) |
| Volume | 39 |
| Issue number | 1 |
| State | Published - Jan 2025 |
Fingerprint
Dive into the research topics of '3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver